Announcements Trials
Browse Landscape

Status

Unknown 2Completed 2Approved for marketing 2Available 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Expanded_access 2

Sponsor

Cancer Type

CNS 2Endocrine 1

Conditions

Pheochromocytoma 1Paraganglioma 1Neuroblastoma 1

Interventions

Afatinib 3niraparib 2lenvatinib 2ibrutinib 2abemaciclib 2Trastuzumab 2Sunitinib 2Ramucirumab 2Gefitinib 2Capecitabine 2Abiraterone Acetate 23-Iodobenzylguanidine 2zenocutuzumab 1vorasidenib 1tucatinib 1trilaciclib 1trifluridine tipiracil drug combination 1tovorafenib 1talquetamab 1tafasitamab 1selpercatinib 1sacituzumab govitecan 1ripretinib 1pralsetinib 1ponatinib 1pomalidomide 1pirtobrutinib 1pertuzumab 1olaratumab 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Approved for marketing × INDUSTRY × 3-Iodobenzylguanidine × Clear all
NCT02961491 2019-01-30

Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Molecular Insight Pharmaceuticals, Inc.

Approved for marketing
CNSEndocrine

Paraganglioma, Pheochromocytoma

NCT00730444 2009-11-09

Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma

GE Healthcare

Approved for marketing
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡